Jason Meyenburg is the founder of Gemini Therapeutics. Gemini Therapeutics has raised $216M in total funding. Latest round: IPO.
Jason Meyenburg was the Chief Executive Officer of Gemini Therapeutics, a precision medicine company focused on age-related macular degeneration. The company went public on the Nasdaq Exchange in February 2021 through a merger with FS Development Corp., a SPAC sponsored by Foresite Capital.
Full founder directory · Investor directory · Company funding database · Fundraising library
The Startup Fundraising Platform
Raise funds for your startup
Find the right investors and get real replies — instantly, powered by AI.
Takes 30 seconds · No credit card · Cancel anytime
Slide-by-slide guide